Sangamo Therapeutics, Inc.
SGMO
$0.4831
-$0.0169-3.38%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 6.44M | 7.55M | 49.41M | 356.00K | 481.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.44M | 7.55M | 49.41M | 356.00K | 481.00K |
| Cost of Revenue | 26.00M | 23.68M | 27.73M | 24.82M | 35.89M |
| Gross Profit | -19.57M | -16.12M | 21.68M | -24.47M | -35.41M |
| SG&A Expenses | 10.06M | 9.77M | 8.65M | 14.75M | 11.77M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 36.06M | 33.44M | 36.38M | 39.57M | 47.66M |
| Operating Income | -29.63M | -25.89M | 13.03M | -39.21M | -47.18M |
| Income Before Tax | -30.48M | -23.82M | 10.76M | -36.05M | -48.99M |
| Income Tax Expenses | 119.00K | -427.00K | 88.00K | 74.00K | 98.00K |
| Earnings from Continuing Operations | -30.60M | -23.40M | 10.67M | -36.13M | -49.09M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -30.60M | -23.40M | 10.67M | -36.13M | -49.09M |
| EBIT | -29.63M | -25.89M | 13.03M | -39.21M | -47.18M |
| EBITDA | -28.61M | -24.65M | 14.25M | -37.97M | -45.77M |
| EPS Basic | -0.14 | -0.11 | 0.05 | -0.17 | -0.27 |
| Normalized Basic EPS | -0.09 | -0.07 | 0.04 | -0.12 | -0.15 |
| EPS Diluted | -0.14 | -0.12 | 0.04 | -0.17 | -0.27 |
| Normalized Diluted EPS | -0.09 | -0.07 | 0.04 | -0.12 | -0.15 |
| Average Basic Shares Outstanding | 220.27M | 210.19M | 208.35M | 203.95M | 180.34M |
| Average Diluted Shares Outstanding | 220.27M | 210.19M | 214.33M | 203.95M | 180.34M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |